Drug
Nimotuzumab clinical trials
Keep track of what changes. Save the nimotuzumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
127 studies that test it; most in 2009 (13)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 13 |
| 2010 | 4 |
| 2011 | 8 |
| 2012 | 3 |
| 2013 | 7 |
| 2014 | 5 |
| 2015 | 10 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 3 |
| 2020 | 5 |
| 2021 | 8 |
| 2022 | 6 |
| 2023 | 7 |
| 2024 | 9 |
| 2025 | 10 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 114
Biotech Pharmaceutical Co., Ltd. (20) · Sun Yat-sen University (8) · Peking University (7) · Tianjin Medical University Cancer Institute and Hospital (7) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (6) · Chinese Academy of Medical Sciences (6) · Fudan University (5) · YM BioSciences (5)
Often tested with
Tested in the same studies.
Cisplatin (4) · Irinotecan (3) · Toripalimab (3) · Sintilimab (3) · Gemcitabine (3) · Docetaxel (2) · Adebrelimab (2) · Tegafur (2)
Studies
Open first, then newest update. How each study uses nimotuzumab is read from its arms, and is right about nine times in ten.
Testing it · 127
- Nimotuzumab Plus Radiotherapy in Elderly Patients With Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingPhase 2Ke HuNCT07821242Written as Nimotuzumab
- A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic CancerNot yet recruitingPhase 1/2Zhejiang UniversityNCT07736612Written as Nimotuzumab
- Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual GlioblastomaNot yet recruitingPhase 2Tianjin First Central HospitalNCT07707973Written as nimotuzumab
- Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal CarcinomaRecruitingPhase 3Sun Yat-sen UniversityNCT07706985Written as Nimotuzumab
- Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT07601737Written as Nimotuzumab Injection
- HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer PatientsRecruitingPhase 2Zhejiang UniversityNCT06770452Written as Nimotuzumab
- Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell CarcinomaNot yet recruitingPhase 2/3Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT07535567Written as Nimotuzumab
- Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCCRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07457528Written as Nimotuzumab
- Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal MalignanciesNot yet recruitingPhase 2Chinese PLA General HospitalNCT07446270Written as Pancreatic cancer: Tunlametinib +Nimotuzumab
- Chemoradiotherapy in Esophageal or Esophagogastric Junction CancerRecruitingPhase 3Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04821778Written as Nimotuzumab
- Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar CancerRecruitingPhase 2Tang-Du HospitalNCT07353723Written as Nimotuzumab
- Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaRecruitingPhase 3Shandong Cancer Hospital and InstituteNCT07333274Written as Nimotuzumab
- Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell CarcinomaEnrolling by invitationPhase 2Peking UniversityNCT07312578Written as Nimotuzumab
- Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic CancerNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07277452Written as Nimotuzumab
- Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06509009Written as Nimotuzumab
- Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialRecruitingPhase 2Ming-Yuan ChenNCT07070479Written as Nimotuzumab
- A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell CarcinomaRecruitingPhase 1/2Fudan UniversityNCT07105592Written as Nimotuzumab+Adebrelimab+Chemotherapy
- An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder CancerNot yet recruitingPhase 1Peking University First HospitalNCT07053735Written as Nimotuzumab and Radiotherapy
- Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell CarcinomaRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06988956Written as Nimotuzumab
- TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal CarcinomaRecruitingPhase 2Sun Yat-sen UniversityNCT06912711Written as Nimotuzumab
See all 127 studies that test nimotuzumab →
Given in every arm · 3 — nimotuzumab is usual care beside what is tested
- Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell CarcinomaRecruitingPhase 3Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT07445048Written as Nimotuzumab
- Neoadjuvant Treatment Modalities in Esophageal CancerRecruitingPhase 3Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04821843Written as Nimotuzumab
- A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid TumorsRecruitingPhase 2Suzhou Genhouse Bio Co., Ltd.NCT06322095Written as EGFR Monoclonal antibody
Codes
What other systems call nimotuzumab · ClinicalTrials.gg INT004790
- MeSH (NLM) C501466nimotuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6NS400BXKHNIMOTUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3877039nimotuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2733NimotuzumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C501466 | nimotuzumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6NS400BXKH | NIMOTUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3877039 | nimotuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2733 | Nimotuzumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.